All In Biotech

Drug Trial Radar · NCT01707381

BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension

A Randomized, Single-Center, Open-Label, Crossover Study Comparing the Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension.

Last checked: Nov 20, 2026Latest source record: Sep 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

25

Actual

Start

Nov 2012

Primary completion

Dec 2013

Study completion Feb 2014

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
Oct 16, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 40 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical investigation is being performed to compare the effect of BOL-303259-X dosed once daily (QD) with timolol maleate 0.5% dosed twice daily (BID) in reducing intraocular pressure (IOP) measured over a 24-hour period in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Conditions

  • Ocular Hypertension
  • Open Angle Glaucoma

Interventions

  • BOL-303259-XDrug

    Topical ophthalmic solution

  • Timolol maleateDrug

    Topical ophthalmic solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 24 Hour IOPTime frame: after 4 weeks of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of California San Diego

    La Jolla, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.